Zacks Research Decreases Earnings Estimates for Chemours

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

The Chemours Company (NYSE:CC - Free Report) - Investment analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Chemours in a report released on Monday, August 18th. Zacks Research analyst Team now forecasts that the specialty chemicals company will post earnings of $1.30 per share for the year, down from their prior forecast of $1.32. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q4 2025 earnings at $0.26 EPS, Q1 2027 earnings at $0.48 EPS and Q2 2027 earnings at $0.75 EPS.

Several other equities research analysts also recently weighed in on the company. Barclays lowered their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Morgan Stanley lowered their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. The Goldman Sachs Group lowered their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 14th. Mizuho upped their target price on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.38.

Chemours Stock Up 8.4%

NYSE CC traded up $1.1930 during trading on Tuesday, hitting $15.3430. The company's stock had a trading volume of 4,286,614 shares, compared to its average volume of 4,534,313. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The company has a market cap of $2.30 billion, a PE ratio of -5.48 and a beta of 1.61. The business's 50 day simple moving average is $12.90 and its 200-day simple moving average is $12.88. Chemours has a fifty-two week low of $9.13 and a fifty-two week high of $22.38.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The company had revenue of $1.62 billion during the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm's revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Chemours Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.3%. Chemours's dividend payout ratio is presently -12.50%.

Insider Activity at Chemours

In other news, CEO Denise Dignam bought 4,068 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Damian Gumpel bought 13,400 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was purchased at an average price of $9.22 per share, for a total transaction of $123,548.00. Following the transaction, the insider owned 123,879 shares of the company's stock, valued at approximately $1,142,164.38. This represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 25,290 shares of company stock worth $250,437. Company insiders own 0.34% of the company's stock.

Hedge Funds Weigh In On Chemours

Several hedge funds and other institutional investors have recently made changes to their positions in CC. Wells Fargo & Company MN lifted its position in shares of Chemours by 7.0% in the fourth quarter. Wells Fargo & Company MN now owns 84,369 shares of the specialty chemicals company's stock valued at $1,426,000 after acquiring an additional 5,540 shares in the last quarter. Invesco Ltd. lifted its position in shares of Chemours by 141.5% in the fourth quarter. Invesco Ltd. now owns 1,020,001 shares of the specialty chemicals company's stock valued at $17,238,000 after acquiring an additional 597,638 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Chemours by 7.3% in the fourth quarter. Renaissance Technologies LLC now owns 288,400 shares of the specialty chemicals company's stock valued at $4,874,000 after acquiring an additional 19,500 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Chemours in the fourth quarter valued at approximately $2,283,000. Finally, Sterling Capital Management LLC lifted its position in shares of Chemours by 54.8% in the fourth quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock valued at $143,000 after acquiring an additional 2,991 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.